The study was conducted by the CAPRISA
consortium, including the National Institute for Communicable Diseases in Johannesburg, the University of KwaZulu-Natal and the University of Cape Town, in partnership with the US Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and Columbia University.
7) Given results of CAPRISA
004, the next step is to try to conduct an expanded safety studies in youth using antiretroviral-based microbicides.
The trial was run by the Centre for the AIDS Programme of Research in South Africa or CAPRISA
at the University of KwaZulu-Natal in Durban, South Africa.
Salim Abdool Karim, President of the South African Medical Research Council and Director of CAPRISA
(Center for the AIDS Program of Research in South Africa) at the University of KwaZulu-Natal said, "By increasing its reach in Africa, GVN is well-placed to make an impact with innovative solutions to a number of human viral diseases that threaten Africa and beyond.
In 2011, for example, the VOICE trial was unable to confirm the CAPRISA
finding that a tenofovir-based vaginal microbicide gel could protect women from infection.
The results of the CAPRISA
004 study released in July 2010 were an important milestone in the search for an effective microbicide.
The recent results from the iPrEx trial showed that PrEP is effective in gay men and transgender women, while the CAPRISA
004 microbicide trial showed that 1% tenofovir gel is effective at reducing HIV risk for women.
004 trial, the first trial to assess the effectiveness of a 1 per cent vaginal gel formulation of tenofovir as a potential microbicide, was a double-blind, randomized placebo-controlled trial which included 889 rural and urban South African women (ages 18 to 40 yr) who were sexually active and HIV-negative.
[Center for the MDS Program of Research in South Africa ] 004 study is the first step.
Data Source: CAPRISA
004, a randomized, placebo-controlled study of 843 women.
associate director of CAPRISA
and an epidemiologist at Columbia, who ran the study with her husband and reported the results along with him.
004 enrolled 980 South African women with a high HIV risk and randomized them to use 1% tenofovir gel or placebo.